[go: up one dir, main page]

WO1999035165A1 - Proteines secretees et polynucleotides les codant - Google Patents

Proteines secretees et polynucleotides les codant Download PDF

Info

Publication number
WO1999035165A1
WO1999035165A1 PCT/US1999/000338 US9900338W WO9935165A1 WO 1999035165 A1 WO1999035165 A1 WO 1999035165A1 US 9900338 W US9900338 W US 9900338W WO 9935165 A1 WO9935165 A1 WO 9935165A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nucleotide
polynucleotide
sequence
nucleotide sequence
Prior art date
Application number
PCT/US1999/000338
Other languages
English (en)
Inventor
Kenneth Jacobs
John M. Mccoy
Edward R. Lavallie
Lisa A. Collins-Racie
Cheryl Evans
David Merberg
Maurice Treacy
Michael J. Agostino
Robert J. Ii Steininger
Gordon G. Wong
Hilary Clark
Kim Fechtel
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Priority to EP99900791A priority Critical patent/EP1044220A1/fr
Priority to JP2000527560A priority patent/JP2002500037A/ja
Priority to AU20296/99A priority patent/AU2029699A/en
Priority to CA002316775A priority patent/CA2316775A1/fr
Publication of WO1999035165A1 publication Critical patent/WO1999035165A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:4.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:4;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 194 to amino acid 203 of SEQ ID NO:8.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO: 16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 64 to amino acid 73 of SEQ
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 72 to amino acid 81 of SEQ ID NO:18.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 374 to nucleotide 415, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 19 from nucleotide 374 to nucleotide 415, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 374 to nucleotide 415.
  • nm214_3 A polynucleotide of the present invention has been identified as clone "nm214_3".
  • nm214_3 was isolated from a human adult blood (erythroleukemia TF-1) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • nm214_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "nm214_3 protein").
  • the oligonucleotide should preferably be labeled with ⁇ - 32 P ATP (specific activity 6000
  • MLR Mixed lymphocyte reaction
  • Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells.
  • a protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.
  • Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.
  • a protein of the invention may also exhibit hemostatic or thrombolytic activity.
  • compositions used to practice the method of the present invention should contain about 0.01 ⁇ g to about 100 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 ⁇ g to about 1 mg) of protein of the present invention per kg body weight.
  • the amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
  • proteins of the invention may be combined with other agents beneficial to the treatment of the bone and /or cartilage defect, wound, or tissue in question.
  • Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention a trait à de nouveaux polynucléotides ainsi qu'aux protéines codées par ceux-ci.
PCT/US1999/000338 1998-01-08 1999-01-07 Proteines secretees et polynucleotides les codant WO1999035165A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99900791A EP1044220A1 (fr) 1998-01-08 1999-01-07 Proteines secretees et polynucleotides les codant
JP2000527560A JP2002500037A (ja) 1998-01-08 1999-01-07 分泌蛋白およびそれらをコードするポリヌクレオチド
AU20296/99A AU2029699A (en) 1998-01-08 1999-01-07 Secreted proteins and polynucleotides encoding them
CA002316775A CA2316775A1 (fr) 1998-01-08 1999-01-07 Proteines secretees et polynucleotides les codant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7075598P 1998-01-08 1998-01-08
US60/070,755 1998-01-08
US22558599A 1999-01-06 1999-01-06
US09/225,585 1999-01-06

Publications (1)

Publication Number Publication Date
WO1999035165A1 true WO1999035165A1 (fr) 1999-07-15

Family

ID=26751469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000338 WO1999035165A1 (fr) 1998-01-08 1999-01-07 Proteines secretees et polynucleotides les codant

Country Status (5)

Country Link
EP (1) EP1044220A1 (fr)
JP (1) JP2002500037A (fr)
AU (1) AU2029699A (fr)
CA (1) CA2316775A1 (fr)
WO (1) WO1999035165A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012708A3 (fr) * 1998-09-01 2001-10-04 Genentech Inc Nouveaux pro-polypeptides et sequences correspondantes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AYALA F. J., ET AL.: "CHOMOSOMAL MUTATIONS.", MODERN GENETICS, XX, XX, vol. 575., no. 01., 1 January 1984 (1984-01-01), XX, pages 694., XP002920788 *
DATABASE MPSRCH GENBANK 1 January 1900 (1900-01-01), XP002920785, Database accession no. H12643 *
DATABASE MPSRCH GENBANK 1 January 1900 (1900-01-01), XP002920786, Database accession no. AA230132 *
DATABASE MPSRCH GENBANK 1 January 1900 (1900-01-01), XP002920787, Database accession no. AC005703 *
JACOBS K A, ET AL.: "A GENETIC SELECTION FOR ISOLATING CDNAS ENCODING SECRETED PROTEINS", GENE., ELSEVIER, AMSTERDAM., NL, vol. 198, 1 October 1997 (1997-10-01), NL, pages 289 - 296, XP002045919, ISSN: 0378-1119, DOI: 10.1016/S0378-1119(97)00330-2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012708A3 (fr) * 1998-09-01 2001-10-04 Genentech Inc Nouveaux pro-polypeptides et sequences correspondantes

Also Published As

Publication number Publication date
JP2002500037A (ja) 2002-01-08
EP1044220A1 (fr) 2000-10-18
AU2029699A (en) 1999-07-26
CA2316775A1 (fr) 1999-07-15

Similar Documents

Publication Publication Date Title
WO2000055375A1 (fr) Proteines secretees et polynucleotides les codant
WO1999042470A1 (fr) Proteines secretees et polynucleotides codant lesdites proteines
WO1999050405A1 (fr) Proteines secretees et polynucleotides les codant
EP1075487A1 (fr) Proteines secretees et polynucleotides les codant
WO1999007840A1 (fr) Proteines secretees et polynucleotides les codant
EP1053252A1 (fr) Proteines secretees et polynucleotides les codant
EP1062233A1 (fr) Proteines secretees et polynucleotides les codant
EP1040118A1 (fr) Proteines secretees et polynucleotides les codant
WO2000050592A1 (fr) Proteines secretees et polynucleotides les codant
EP1049770A1 (fr) Proteines secretees et polynucleotides les codant
WO1999018127A1 (fr) Proteines secretees et polynucleotides les codant
EP1032594A1 (fr) Proteines secretees et polynucleotides les codant
WO1999053045A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
EP1064302A1 (fr) Proteines secretees et polynucleotides les codant
WO1999037674A1 (fr) Proteines secretees et polynucleotides les codant
EP1068308A1 (fr) Proteines secretees et polynucleotides codant pour ces proteines
WO1999038959A1 (fr) Proteines secretees et polynucleotides codant pour elles
WO1999035165A1 (fr) Proteines secretees et polynucleotides les codant
WO1999032614A1 (fr) Proteines secretees et polynucleotides les codant
WO1999024469A1 (fr) Proteines secretees et polynucleotides les codant
WO1999013066A1 (fr) Proteines secretees et polynucleotides les codant
EP1268834A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
EP1047772A1 (fr) Proteines secretees et polynucleotides les codant
EP1177440A1 (fr) Proteines secretees et polynucleotides codant ces dernieres
WO1999028335A1 (fr) Proteines secretees et polynucleotides les codant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2316775

Country of ref document: CA

Ref country code: CA

Ref document number: 2316775

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 527560

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999900791

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999900791

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999900791

Country of ref document: EP